Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure

Pil, Lore; Hoorens, Isabelle; Vossaert, Katrien; Krüse, Vibeke; Tromme, Isabelle; Speybroeck, Niko; Brochez, Liève; Annemans, Lieven

doi:10.1016/j.ypmed.2016.10.005

Cited by 40 publications

(61 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pil et al 35 have previously modelled the effect of various scenarios thought to prevent skin cancer. Our results are based on an actual intervention with measurable results of the exposure; therefore, our modelling results of the future cancer incidence are a realistic prognosis of the incidence change.…”

Section: Discussionmentioning

confidence: 99%

Sunbed use 2007–2015 and skin cancer projections of campaign results 2007–2040 in the Danish population: repeated cross-sectional surveys

Køster¹,

Meyer²,

Andersson

et al. 2018

BMJ Open

View full text Add to dashboard Cite

ObjectiveTo evaluate the effect of the Danish Sun Safety Campaign 2007–2015 on the prevalence of sunbed use and to model future effects on the skin cancer incidences 2007–2040.DesignThe study has a repeated, cross-sectional design.SettingExposure to ultraviolet radiation is the main risk factor for skin cancer. Denmark has the highest prevalence of sunbed use reported and one of the highest incidences of skin cancer worldwide.ParticipantsDuring 2007–2015, survey data were collected for 37 766 Danes, representative of the Danish population with regards to age, gender and region.InterventionsIn 2007, an ongoing long-term antisunbed campaign was launched in Denmark.Primary and secondary outcome measuresSunbed use was evaluated by annual cross-sectional surveys. Skin cancer incidence was modelled in the Prevent programme, using population projections, historic cancer incidence, sunbed use exposure and relative risk of sunbed use on melanoma.ResultsThe prevalence of recent sunbed use in Denmark was reduced from 32% and 18% to 13% and 8% for women and men, respectively. The campaigns results during 2007–2015 are estimated to reduce the number of skin cancer cases from more than 5000 (746malignant melanoma, 1562 SCC, 2673 BCC) totally during 2007–2040. Keeping the 2015 level of sunbed use constant by continued campaign pressure or introduction of structural interventions would potentially prevent more than 750 skin cancer cases annually in 2040 and 16 000 skin cancer cases in total during 2007–2040.ConclusionWe have shown the value of prevention and of long-term planning in prevention campaigning. Sunbed use was reduced significantly during 2007–2015 and further reductions are possible by structural interventions. Consequently, significantly fewer skin cancer cases are anticipated during 2007–2040. The Danish Parliament has population support to enforce structural interventions to avoid a large burden of this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Sunbed use 2007–2015 and skin cancer projections of campaign results 2007–2040 in the Danish population: repeated cross-sectional surveys

Køster¹,

Meyer²,

Andersson

et al. 2018

BMJ Open

View full text Add to dashboard Cite

show abstract

“…21 Further, in one incremental cost study, healthy controls were matched for age and sex, but not for any other variables such as comorbidity. 21 Thus, in some studies, the difference between costs in the general population and in melanoma patients may 20 be attributable to diseases other than melanoma. For instance, patients on an immunosuppressive therapy (such as treatment for HIV, other malignant diseases or after organ transplantation) are known to be prone to skin cancer and require a cost-intensive treatment.…”

Section: Discussionmentioning

confidence: 99%

Cost‐of‐illness of melanoma in Europe – a systematic review of the published literature

Schäfer

Augustin

2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Malignant melanoma accounts for the vast majority of skin cancer deaths. Primary prevention is used to increase knowledge about skin cancer and set incentives for a change in behaviour, which leads to a decrease in cases. Primary prevention may be cost‐effective or even cost saving. Cost‐of‐illness (COI) studies provide information on such potential savings. The purpose of this study is to give an overview on COI studies in European countries and to compare the COI in total and by cost categories. The results can be used to model potential cost savings from prevention. We conducted a systematic literature research in PubMed using the PRISMA checklist. All costs were converted into Euro and adjusted for the reference year 2012. For the ranking of countries according to their COI, all costs were adjusted for the purchasing power parity. All studies focusing on stage III–IV melanoma include information on hospital, hospice, and outpatient treatment. Costs for the treatment of advanced melanoma range between € 2972 in Italy and € 17 408 in Sweden after adjusting for purchasing power parity. Most studies on stage I–IV melanoma include costs of hospitalization, outpatient treatment and general practitioner consultation. Direct costs range from € 923 in Sweden to € 9829 in Denmark. Three articles also include information on indirect costs. Mortality costs vary between € 3511 in Sweden and € 20 408 in England, morbidity costs between € 103 in Sweden and € 4550 in England. We showed that costs for the treatment of skin cancer are moderately high in the included countries. Since after publication of the articles new costly drugs were approved in Europe, treatment costs of melanoma in Europe may be expected to have risen in the last few years, which means that there is a high expectable potential for prevention programmes to become cost‐effective or even cost saving.

show abstract

“…In 2017, the overall prevalence of sunbed use in Belgium was 27% for the population aged between 15 and 65 years, where the number of frequent users declined from 13% in 2011 to 7% in 2017. 8 This reflects a total of over 1 million persons having used sunbeds during the past year. A surprising 47% of the Belgian population between 15 and 65 years of age have ever used sunbeds at least once in their lives.…”

Section: Strategic Context and Needmentioning

confidence: 99%

Cancer league actions against sunbed use for skin cancer prevention

Yared

Boonen²,

McElwee

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

The incidence of non‐melanoma and melanoma skin cancer has been rising in Europe. Although the World Health Organization's International Agency for Research on Cancer has since 2009 classified sunbeds as a Group 1 carcinogen, sunbed use, especially by those under the age of 18, continues to be a concern. As the only platform for cancer leagues in Europe, the Association of European Cancer Leagues decided to explore interest and actions by its member leagues at the national level against sunbed use, to share experiences and to provide background information on possible future collective actions at the EU level.

show abstract

Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure

Cited by 40 publications

References 22 publications

Sunbed use 2007–2015 and skin cancer projections of campaign results 2007–2040 in the Danish population: repeated cross-sectional surveys

Sunbed use 2007–2015 and skin cancer projections of campaign results 2007–2040 in the Danish population: repeated cross-sectional surveys

Cost‐of‐illness of melanoma in Europe – a systematic review of the published literature

Cancer league actions against sunbed use for skin cancer prevention

Contact Info

Product

Resources

About